Poh et al. identified two specific effects of LY30 that might explainits ability to sensitize HeLa carcinoma cells to TRAIL (Poh et al., 2007): (i) clustering of TRAILreceptors, and (ii) down-regulating the pro-survival protein cFLIP. The gene discussed is TNFSF10; the disease is carcinoma.